Grace Therapeutics, Inc.
About Grace Therapeutics, Inc.
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2022
- $100.0M
- Net income
- -$9.6M
- Total assets
- $72.0M
- Market cap
- $35.6M
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Operating income
- -$16.7M
- Income tax
- -$3.2M
- Net income
- -$9.6M
- EPS (basic)
- $-0.79
- EPS (diluted)
- $-0.79
Balance sheet
- Total assets
- $72.0M
- Current assets
- $22.7M
- Total liabilities
- $5.4M
- Current liabilities
- $1.9M
- Shareholders’ equity
- $66.6M
Cash flow
- Operating cash flow
- -$14.9M
- Investing cash flow
- $872.0K
- Financing cash flow
- $14.0M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $35.6M
- EPS (diluted)
- $-0.79
- Shares outstanding
- 15.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 26, 2011
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $9.6M in FY2022.
- Trading 55% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Grace Therapeutics, Inc..
Write a review
News about Grace Therapeutics, Inc.
News & sentiment via Polygon.io
